PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond

被引：38
|
作者：
Banerjee, Susana [2 ]
Kaye, Stan [1 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Div Clin Studies, Inst Canc Res, Drug Dev Unit, Sutton SM2 5PT, Surrey, England
[2] Royal Marsden NHS Fdn Trust, Gynaecol Unit, Sutton SM2 5PT, Surrey, England
来源：
CURRENT ONCOLOGY REPORTS | 2011年 / 13卷 / 06期
关键词：
PARP inhibitors; Ovarian cancer; BRCA; Olaparib; Endometrial; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; MUTANT-CELLS; TUMOR; MUTATIONS; CARCINOMA; FEATURES; DELETION; REPAIR;
D O I：
10.1007/s11912-011-0193-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation-associated ovarian and breast cancer. This approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in cancers that harbor mutations in the BRCA1 or BRCA2 genes. Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic, high-grade serous ovarian cancers and other cancers including endometrial cancer. In this review, we discuss the clinical development of PARP inhibitors in ovarian cancer and explore challenges that need to be addressed if the full potential of these agents is to be realized.
引用
收藏
页码：442 / 449
页数：8
相关论文
共 50 条
  • [31] PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy
    Matsumoto, Koji
    Nishimura, Meiko
    Onoe, Takuma
    Sakai, Hideki
    Urakawa, Yusaku
    Onda, Takashi
    Yaegashi, Nobuo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (08) : 703 - 707
  • [32] PARP Inhibitors in Ovarian Cancer
    Mittica, Gloria
    Ghisoni, Eleonora
    Giannone, Gaia
    Genta, Sofia
    Aglietta, Massimo
    Sapino, Anna
    Valabrega, Giorgio
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2018, 13 (04) : 392 - 410
  • [33] PARP inhibitors in ovarian cancer
    David Cibula
    Judith Balmaña
    British Journal of Cancer, 2015, 113 : S1 - S2
  • [34] PARP inhibitors in ovarian cancer
    Goldlust, Ian S.
    Guidice, Elena
    Lee, Jung-min
    SEMINARS IN ONCOLOGY, 2024, 51 (1-2) : 45 - 57
  • [35] PARP Inhibitors in Ovarian Cancer
    da Costa, Alexandre
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (16): : 1572 - 1573
  • [36] PARP Inhibitors for Ovarian Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1535): : 200 - 202
  • [37] PARP INHIBITORS IN OVARIAN CANCER
    Calvert, H.
    Curtin, N.
    Plummer, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 23 - 23
  • [38] PARP inhibitors in ovarian cancer
    Ledermann, J. A.
    ANNALS OF ONCOLOGY, 2016, 27 : 40 - 44
  • [39] PARP inhibitors in ovarian cancer
    Franzese, Elisena
    Centonze, Sara
    Diana, Anna
    Carlino, Francesca
    Guerrera, Luigi Pio
    Di Napoli, Marilena
    De Vita, Ferdinando
    Pignata, Sandro
    Ciardiello, Fortunato
    Orditura, Michele
    CANCER TREATMENT REVIEWS, 2019, 73 : 1 - 9
  • [40] POTENTIAL TARGETED THERAPIES FOR OVARIAN CANCER BEYOND PARP INHIBITORS (REVIEW)
    Sisman, Yagmur
    Hogdall, Dan
    Henrichsen, Tine Schnack
    Hogdall, Claus
    Hogdall, Estrid
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A286 - A287
12345